Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 16c, Misses on Revenue; Offers FY24 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Revenue Growth %: +6.2%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +6.2%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.38, $0.16 better than the analyst estimate of $0.22. Revenue for the quarter came in at $98.44 million versus the consensus estimate of $99.03 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2024 revenue of $455-475 million, versus the consensus of $460.5 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
- Raymond James Upgrades Dollar Tree (DLTR) to Outperform
- Barclays Downgrades HCA Healthcare Inc (HCA) to Equalweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
